Hila Magen

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo et al. · New England Journal of Medicine · 2015 · 1.3K citations · Full text

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Guy Ledergor, Assaf Weiner, Mor Zada et al. · Nature Medicine · 2018 · 271 citations · Full text

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 231 citations

Hematological Malignancy, Surgical Oncology, Medicine +6

Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch et al. · Haematologica · 2018 · 207 citations · Full text

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Meletios Α. Dimopoulos, Sagar Lonial, Darrell White et al. · Blood Cancer Journal · 2020 · 151 citations · Full text